CTSH
60
-3
GME
66
-5
TMO
42
-6
HCP
56
-8
EXR
57
2
MRO
50
4
MAS
52
-4
CRM
60
-7
ESS
62
-3
ZTS
47
2
FE
44
5
R
70
-3
DLTR
38
-4
CSX
57
-4
STI
45
26
GT
56
-3
STT
64
2
NAVI
52
-2
CMS
60
2
DOV
65
-4
CTSH
60
-3
GME
66
-5
TMO
42
-6
HCP
56
-8
EXR
57
2
MRO
50
4
MAS
52
-4
CRM
60
-7
ESS
62
-3
ZTS
47
2
FE
44
5
R
70
-3
DLTR
38
-4
CSX
57
-4
STI
45
26
GT
56
-3
STT
64
2
NAVI
52
-2
CMS
60
2
DOV
65
-4
Financhill
Back

Aytu BioPharma 10K Form

Sell
37

AYTU
Aytu BioPharma

Last Price:
1.52
Seasonality Move:
12.49%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AYTU News And Ratings

See the #1 stock for the next 7 days that we like better than AYTU

AYTU Financial Statistics

Sales & Book Value

Annual Sales: $81M
Cash Flow: $-788K
Price / Cash Flow: 0
Annual Sales: $4.64
Price / Book: 0.34

Profitability

EPS (TTM): -2.86000
Net Income (TTM): $-15.84M
Gross Margin: $54.59M
Return on Equity: -48.64%
Return on Assets: -12.23%

Aytu BioPharma Earnings Forecast

Key Aytu BioPharma Financial Ratios

  • The Gross Profit Margin over the past 18 years for AYTU is 67.39%.
  • The Selling, General & Administrative Expenses for AYTU have been equal to 61.08% of Gross Profit Margin.
  • The Research & Development expenses have been 3.45% of Revenue.
  • The Interest Expense is -30.24% of Operating Income.
  • The Net Earning history of AYTU is -19.56% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 7 years.

Aytu BioPharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AYTU
CUSIP: 054754
Website: aytubio.com

Debt

Debt-to-Equity Ratio: 0.55
Current Ratio: 0.99
Quick Ratio: 0.7

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AYTU Technical Analysis vs Fundamental Analysis

Sell
37
Aytu BioPharma (AYTU) is a Sell

Is Aytu BioPharma a Buy or a Sell?

  • Aytu BioPharma stock is rated a Sell
    The current Aytu BioPharma [AYTU] share price is $1.55. The Score for AYTU is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.